Skip to content

Live Events
Sign Up / Login

Live Events
Sign Up / Login

Plus Library

By pinki@katapult.biz / February 13, 2025

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 426 - 450 of 2,875

«
1
…
16
17
18
19
20
…
115
»

HER2 Targeted Therapies: Recent Advances

HER2 Targeted Therapies: Recent Advances

Helen Chew, MD, FACP

HER2 Targeted Therapies: Recent Advances

HER2 Targeted Therapies: Recent Advances

Helen Chew, MD, FACP

Cell Cycle and Immune Check Point Inhibitors | Research, Clinic, Patient

Cell Cycle and Immune Check Point Inhibitors | Research, Clinic, Patient

Hope Rugo, MD

Immunotherapy and Optimal Chemotherapy for Early Stage TNBC: When and in Whom?

Immunotherapy and Optimal Chemotherapy for Early Stage TNBC: When and in Whom?

Hope Rugo, MD, FASCO

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Hope S. Rugo, MD, FASCO

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Hope S. Rugo, MD, FASCO

Maturity of the Patient and evolving treatment options

Maturity of the Patient and evolving treatment options

Hyman Muss, MD

ILC, When Non-scary Becomes Scary

ILC, When Non-scary Becomes Scary

Jason Aboudi Mouabbi, MD

New Biomarkers in Breast Cancer

New Biomarkers in Breast Cancer

Joanne Mortimer, MD, FACP, FASCO

New Biomarkers in Breast Cancer

New Biomarkers in Breast Cancer

Joanne Mortimer, MD, FACP, FASCO

Role of Radiation in breast cancer

Role of Radiation in breast cancer

Joe Panoff, MD

Endocrine Therapy for Early -and Late- Stages Breast Cancer: Therapeutic Updates

Endocrine Therapy for Early -and Late- Stages Breast Cancer: Therapeutic Updates

Joyce O’Shaughnessy, MD

Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies (Part 2)

Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies (Part 2)

Joyce O’Shaughnessy, MD

New Directions In Chemotherapy and Immunotherapy for HR+ Breast Cancer

New Directions In Chemotherapy and Immunotherapy for HR+ Breast Cancer

Joyce O’Shaughnessy, MD

Antibody Drug Conjugates Expanding a Targeted Assault on all Breast Cancer Subtypes

Antibody Drug Conjugates Expanding a Targeted Assault on all Breast Cancer Subtypes

Komel Jhaveri, MD

HER2 LOW Advanced and Metastatic Breast Cancer | How Low Do You Go?

HER2 LOW Advanced and Metastatic Breast Cancer | How Low Do You Go?

Komel Jhaveri, MD

Breast Cancer Screening – Updates in Research and liquid Biopsy

Breast Cancer Screening – Updates in Research and liquid Biopsy

Kristina Rinker, PhD

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Lajos Puzstai, MD, DPhil, FASCO

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)

Lajos Puzstai, MD, DPhil, FASCO

Post-Neoadjuvant Therapy after Residual Disease: How to Approach This Problem?

Post-Neoadjuvant Therapy after Residual Disease: How to Approach This Problem?

Lauren Carcas, MD

Post-Neoadjuvant Therapy after Residual Disease: How to Approach This Problem?

Post-Neoadjuvant Therapy after Residual Disease: How to Approach This Problem?

Lauren Carcas, MD

CNS METS- Evolving Multidisciplinary Tumor Board Conversations Radiation Oncology

CNS METS- Evolving Multidisciplinary Tumor Board Conversations Radiation Oncology

Linda Chen, MD

New Endocrine and Targeted Agents for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

New Endocrine and Targeted Agents for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Maria Theodoulou, MD

New Endocrine and Targeted Agents for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

New Endocrine and Targeted Agents for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Maria Theodoulou, MD

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer

Mariana Chavez MacGregor, MD, MSc, FASCO

«
1
…
16
17
18
19
20
…
115
»

Post navigation

← Previous View

6619 South Dixie Highway #341
Miami, FL 33143

Phone: 305.663.1628
Email: info@meccinc.com

Useful Links

Library
Live Events

Categories

MEC Basic
MEC Plus
Purchased

About Us

Why Subscribe
About Us
Accreditation

© 2025 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok